CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04647916
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:52.895435+00:00
Published At: 2025-04-24T00:00:00+00:00
Record Updated At: 2025-04-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Anatomic Stage IV Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Metastatic HER2 Negative Breast Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Prognostic Stage IV Breast Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-04-24"
protocolSection.identificationModule.nctId: "NCT04647916"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.